Clinical Trial Metrics: The Complexity of Conducting Clinical Trials in North American Cancer Centers
Werner, Theresa L
Deal, Allison M
Krise-Confair, Cassandra J
Bentz, Tricia Adrales
Cummings, Theresa M
Grant, Stefan C
Lee, Ashley Baker
Hofacker, Janie K
JournalJCO Oncology Practice
PublisherAmerican Society of Clinical Oncology
MetadataShow full item record
AbstractPURPOSE: Cancer clinical trials offices (CTOs) support the investigation of cancer prevention, early detection, and treatment at cancer centers across North America. CTOs are a centralized resource for clinical trial conduct and typically use research staff with expertise in four functional areas of clinical research: finance, regulatory, clinical, and data operations. To our knowledge, there are no publicly available benchmark data sets that characterize the size, cost, volume, and efficiency of these offices, nor whether the metrics differ by National Cancer Institute (NCI) designation. The Association of American Cancer Institutes (AACI) Clinical Research Innovation (CRI) steering committee developed a survey to address this knowledge gap. METHODS: An 11-question survey that addressed CTO budget, accrual and trial volume, full-time equivalents (FTEs), staff turnover, and activation timelines was developed by the AACI CRI steering committee and sent to 92 academic cancer research centers in North America (n = 90 in the United States; n = 2 in Canada), with 79 respondents completing the survey (86% completion rate). RESULTS: The number of FTE employees working in the CTOs ranged from 4.5 to 811 (median, 104). The median number of analytic cases (ie, newly diagnosed or received first course of treatment) reported by the main center was 3,856. Annual CTO budgets ranged from $250,000 to $23,900,000 (median, $8.2 million). The median trial activation time, based on 61 centers, was 167 days. The median number of accruals per center was 480 (range, 5-6,271) and median number of trials per center was 282 (range, 31-1,833). Budget and FTE ranges varied by NCI designation. CONCLUSION: The response rate to the survey was high. These data will allow cancer centers to evaluate their CTO infrastructure, funding, portfolio, and/or accrual goals as compared with peers. A wide range in each of the outcomes was noted, in keeping with the wide variation in size and scope of cancer center CTOs across the United States and Canada. These variations may warrant additional investigation.
KeywordNorth American cancer center clinical trial offices
Clinical Trials as Topic--organization & administration
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/14436
- The NCI All Ireland Cancer Conference.
- Authors: Johnston PG, Daly PA, Liu E
- Issue date: 1999
- American Society of Clinical Oncology policy statement: oversight of clinical research.
- Authors: American Society of Clinical Oncology.
- Issue date: 2003 Jun 15
- Effect of increased compulsion on readmission to hospital or disengagement from community services for patients with psychosis: follow-up of a cohort from the OCTET trial.
- Authors: Burns T, Yeeles K, Koshiaris C, Vazquez-Montes M, Molodynski A, Puntis S, Vergunst F, Forrest A, Mitchell A, Burns K, Rugkåsa J
- Issue date: 2015 Oct
- Early-phase clinical trials in the community: results from the national cancer institute community cancer centers program early-phase working group baseline assessment.
- Authors: Zaren HA, Nair S, Go RS, Enos RA, Lanier KS, Thompson MA, Zhao J, Fleming DL, Leighton JC, Gribbin TE, Bryant DM, Carrigan A, Corpening JC, Csapo KA, Dimond EP, Ellison C, Gonzalez MM, Harr JL, Wilkinson K, Denicoff AM
- Issue date: 2013 Mar